Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 10/20 | 0.63 |
| ▸ | MAOA | P21397 | 3/20 | 0.55 |
| ▸ | IDO1 | P14902 | 2/20 | 0.53 |
| ▸ | ACHE | P22303 | 1/20 | 0.51 |
| ▸ | FFAR1 | O14842 | 3/20 | 0.50 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.49 |
| ▸ | GRM5 | P41594 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL257781 | 0.87 | MAOB (0.69) | MAOBMAOAIDO1ACHEFFAR1 | |
| SCHEMBL10866245 | 0.84 | MAOB (0.69) | MAOBMAOAIDO1ACHEFFAR1 | |
| SCHEMBL21480345 | 0.84 | MAOB (0.78) | MAOBMAOAIDO1 | |
| SCHEMBL10204868 | 0.84 | MAOB (0.72) | MAOBMAOAIDO1FFAR1 | |
| SCHEMBL22874550 | 0.83 | MAOB (0.66) | MAOBMAOAIDO1ACHE | |
| SCHEMBL21577878 | 0.83 | MAOB (0.63) | MAOBMAOAIDO1ACHEFFAR1 | |
| SCHEMBL12260914 | 0.83 | MAOB (0.63) | MAOBMAOAIDO1ACHEFFAR1 | |
| SCHEMBL15156233 | 0.83 | MAOB (0.73) | MAOBMAOAIDO1ACHE | |
| SCHEMBL16808972 | 0.83 | MAOB (0.63) | MAOBMAOAIDO1 | |
| Hydrochloric Acid SCHEMBL23235850 | 0.82 | MAOB (0.70) | MAOBMAOAIDO1FFAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11931412-B2 | JAK1 inhibitors and uses thereof | WASHINGTON UNIVERSITY (US) | 2024-03-19 | — | — | US | disclosed |
| US-20210338812-A1 | JAK1 INHIBITORS AND USES THEREOF | WASHINGTON UNIVERSITY (US) | 2021-11-04 | — | — | US | disclosed |
| US-10973913-B2 | JAK inhibitors and uses thereof | WASHINGTON UNIVERSITY (US) | 2021-04-13 | — | — | US | disclosed |
| US-20200282051-A1 | JAK INHIBITORS AND USES THEREOF | WASHINGTON UNIVERSITY (US) | 2020-09-10 | — | — | US | disclosed |
| WO-2017143014-A1 | JAK INHIBITORS AND USES THEREOF | KIM BRIAN (US) | 2017-08-24 | — | — | WO | disclosed |
| US-9650362-B2 | Inhibitors | PROBIODRUG AG (DE) | 2017-05-16 | — | — | US | disclosed |
| US-20160039795-A1 | NOVEL INHIBITORS | VIVORYON THERAPEUTICS N.V. (DE) | 2016-02-11 | — | — | US | disclosed |
| US-9173885-B2 | Inhibitors | PROBIODRUG AG (DE) | 2015-11-03 | — | — | US | disclosed |
| EP-2475428-B1 | HETEROCYLCIC DERIVATIVES AS INHIBITORS OF GLUTAMINYL CYCLASE | PROBIODRUG AG (DE) | 2015-07-01 | — | — | EP | disclosed |
| US-8962860-B2 | Inhibitors of glutaminyl cyclase | PROBIODRUG AG (DE) | 2015-02-24 | — | — | US | disclosed |
| US-8889709-B2 | Use of isoQC inhibitors in the treatment and prevention of inflammatory diseases or conditions | PROBIODRUG AG (DE) | 2014-11-18 | — | — | US | disclosed |
| US-20140065095-A1 | NOVEL INHIBITORS | VIVORYON THERAPEUTICS N.V. (DE) | 2014-03-06 | — | — | US | disclosed |
| US-8486940-B2 | Inhibitors | PROBIODRUG AG (DE) | 2013-07-16 | — | — | US | disclosed |
| US-20110092501-A1 | NOVEL INHIBITORS | PROBIODRUG AG (DE) | 2011-04-21 | — | — | US | disclosed |
| US-20100125086-A1 | USE OF ISOQC INHIBITORS | PROBIODRUG AG (DE) | 2010-05-20 | — | — | US | disclosed |
| US-20100119475-A1 | NOVEL INHIBITORS OF GLUTAMINYL CYCLASE | PROBIODRUG AG (DE) | 2010-05-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100119475-A1 | NOVEL INHIBITORS OF GLUTAMINYL CYCLASE | GLS, GLS2, GLUL | MAOB 1881/4885MAOA 2405/4885IDO1 2838/4885 |
| US-20110092501-A1 | NOVEL INHIBITORS | GLUL, QPCT, GLS | MAOB 928/4885MAOA 1070/4885IDO1 177/4885 |
| US-20210338812-A1 | JAK1 INHIBITORS AND USES THEREOF | JAK1, JAK2, JAK3 | MAOB 3202/4885MAOA 3338/4885IDO1 68/4885 |
| US-20160039795-A1 | NOVEL INHIBITORS | GLUL, QPCT, GLS | MAOB 928/4885MAOA 1070/4885IDO1 177/4885 |
| US-10973913-B2 | JAK inhibitors and uses thereof | JAK2, JAK1, JAK3 | MAOB 1829/4885MAOA 2213/4885IDO1 90/4885 |
| US-11931412-B2 | JAK1 inhibitors and uses thereof | JAK1, JAK3, JAK2 | MAOB 2462/4885MAOA 2812/4885IDO1 121/4885 |
| US-20140065095-A1 | NOVEL INHIBITORS | GLUL, QPCT, GLS | MAOB 928/4885MAOA 1070/4885IDO1 177/4885 |
| US-20100125086-A1 | USE OF ISOQC INHIBITORS | QPCT, QPCTL, GGCT | MAOB 3452/4885MAOA 3617/4885IDO1 392/4885 |
| US-20200282051-A1 | JAK INHIBITORS AND USES THEREOF | JAK2, JAK1, JAK3 | MAOB 1829/4885MAOA 2213/4885IDO1 90/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.